MicroRNA Regulation Critical for Development of Pediatric Brain Tumors
By Gerald M. Slutzky, PhD Posted on 14 Dec 2016 |

Image: The nCounter system offers a simple, cost-effective way to simultaneously profile hundreds of mRNAs, microRNAs, or DNA targets (Photo courtesy of NanoString).
Cancer researchers have uncovered the critical role played by microRNA regulation in the development of childhood brain tumors.
MicroRNAs (miRNAs) are a small noncoding family of 19- to 25-nucleotide RNAs that regulate gene expression by targeting messenger RNAs (mRNAs) in a sequence specific manner, inducing translational repression or mRNA degradation, depending on the degree of complementarity between miRNAs and their targets. Many miRNAs are conserved in sequence between distantly related organisms, suggesting that these molecules participate in essential processes. In fact, miRNAs have been shown to be involved in the regulation of gene expression during development, cell proliferation, apoptosis, glucose metabolism, stress resistance, and cancer.
Low-grade gliomas and glioneuronal tumors represent the most frequent primary tumors of the central nervous system in children. Unlike many other types of cancerous tumors, these low-grade pediatric gliomas appear to have few genetic mutations, so the molecular basis for their development has been unclear.
Investigators at Johns Hopkins University (Baltimore, MD, USA) chose to examine a possible role for miRNAs in the development of pediatric gliomas, since miRNAs had been identified as molecular regulators of protein expression/translation that could repress multiple mRNAs concurrently through base pairing, and had an important role in other cancers.
The investigators used the NanoString (Seattle, WA, USA) digital counting system to analyze the expression levels of 800 microRNAs in nine low-grade glial and glioneuronal tumor types.
They reported in the October 14, 2016, online edition of the journal Modern Pathology that a set of 61 microRNAs were differentially expressed in tumors compared with normal brain tissues, and several showed levels varying by tumor type. MicroRNAs miR-4488 and miR-1246 were overexpressed in dysembryoplastic neuroepithelial tumors compared with brain tissue and other tumors, while miR-487b was variably under-expressed in pediatric glioma lines compared with human neural stem cells.
The investigators employed lentiviral vectors to overexpress miR-487b in a pediatric glioma cell line. These modified cells were found to be less cancer-like, forming 30% fewer colonies and had decreased levels of some proteins, such as Nestin (neuroectodermal stem cell marker). Nestin is known to be important in both early development and in cancers.
Senior author Dr. Fausto J.Rodriguez, associate professor of pathology at Johns Hopkins University, said, "Physicians might be able to look at the levels of this and other microRNAs in blood or cerebrospinal fluid to test for the presence of cancer. Researchers might also be able to target microRNAs directly, altering their levels to make cancer cells less likely to form tumors. By gaining a better understanding of the fine genetic differences between cancers and healthy tissues, we can develop better therapeutic or prognostic strategies."
Related Links:
Johns Hopkins University
NanoString
MicroRNAs (miRNAs) are a small noncoding family of 19- to 25-nucleotide RNAs that regulate gene expression by targeting messenger RNAs (mRNAs) in a sequence specific manner, inducing translational repression or mRNA degradation, depending on the degree of complementarity between miRNAs and their targets. Many miRNAs are conserved in sequence between distantly related organisms, suggesting that these molecules participate in essential processes. In fact, miRNAs have been shown to be involved in the regulation of gene expression during development, cell proliferation, apoptosis, glucose metabolism, stress resistance, and cancer.
Low-grade gliomas and glioneuronal tumors represent the most frequent primary tumors of the central nervous system in children. Unlike many other types of cancerous tumors, these low-grade pediatric gliomas appear to have few genetic mutations, so the molecular basis for their development has been unclear.
Investigators at Johns Hopkins University (Baltimore, MD, USA) chose to examine a possible role for miRNAs in the development of pediatric gliomas, since miRNAs had been identified as molecular regulators of protein expression/translation that could repress multiple mRNAs concurrently through base pairing, and had an important role in other cancers.
The investigators used the NanoString (Seattle, WA, USA) digital counting system to analyze the expression levels of 800 microRNAs in nine low-grade glial and glioneuronal tumor types.
They reported in the October 14, 2016, online edition of the journal Modern Pathology that a set of 61 microRNAs were differentially expressed in tumors compared with normal brain tissues, and several showed levels varying by tumor type. MicroRNAs miR-4488 and miR-1246 were overexpressed in dysembryoplastic neuroepithelial tumors compared with brain tissue and other tumors, while miR-487b was variably under-expressed in pediatric glioma lines compared with human neural stem cells.
The investigators employed lentiviral vectors to overexpress miR-487b in a pediatric glioma cell line. These modified cells were found to be less cancer-like, forming 30% fewer colonies and had decreased levels of some proteins, such as Nestin (neuroectodermal stem cell marker). Nestin is known to be important in both early development and in cancers.
Senior author Dr. Fausto J.Rodriguez, associate professor of pathology at Johns Hopkins University, said, "Physicians might be able to look at the levels of this and other microRNAs in blood or cerebrospinal fluid to test for the presence of cancer. Researchers might also be able to target microRNAs directly, altering their levels to make cancer cells less likely to form tumors. By gaining a better understanding of the fine genetic differences between cancers and healthy tissues, we can develop better therapeutic or prognostic strategies."
Related Links:
Johns Hopkins University
NanoString
Latest BioResearch News
- Genome Analysis Predicts Likelihood of Neurodisability in Oxygen-Deprived Newborns
- Gene Panel Predicts Disease Progession for Patients with B-cell Lymphoma
- New Method Simplifies Preparation of Tumor Genomic DNA Libraries
- New Tool Developed for Diagnosis of Chronic HBV Infection
- Panel of Genetic Loci Accurately Predicts Risk of Developing Gout
- Disrupted TGFB Signaling Linked to Increased Cancer-Related Bacteria
- Gene Fusion Protein Proposed as Prostate Cancer Biomarker
- NIV Test to Diagnose and Monitor Vascular Complications in Diabetes
- Semen Exosome MicroRNA Proves Biomarker for Prostate Cancer
- Genetic Loci Link Plasma Lipid Levels to CVD Risk
- Newly Identified Gene Network Aids in Early Diagnosis of Autism Spectrum Disorder
- Link Confirmed between Living in Poverty and Developing Diseases
- Genomic Study Identifies Kidney Disease Loci in Type I Diabetes Patients
- Liquid Biopsy More Effective for Analyzing Tumor Drug Resistance Mutations
- New Liquid Biopsy Assay Reveals Host-Pathogen Interactions
- Method Developed for Enriching Trophoblast Population in Samples
Channels
Clinical Chemistry
view channel
New Method Uses Pulsed Infrared Light to Find Cancer's 'Fingerprints' In Blood Plasma
Cancer diagnoses have traditionally relied on invasive or time-consuming procedures like tissue biopsies. Now, new research published in ACS Central Science introduces a method that utilizes pulsed infrared... Read more
Carbon Nanotubes Help Build Highly Accurate Sensors for Continuous Health Monitoring
Current sensors can measure various health indicators, such as blood glucose levels, in the body. However, there is a need to develop more accurate and sensitive sensor materials that can detect lower... Read moreMolecular Diagnostics
view channel
Gene-Based Blood Test Accurately Predicts Tumor Recurrence of Advanced Skin Cancer
Melanoma, an aggressive form of skin cancer, becomes extremely difficult to treat once it spreads to other parts of the body. For patients with metastatic melanoma tumors that cannot be surgically removed... Read more
Blood Test Could Identify Patients at Risk for Severe Scleroderma
Systemic sclerosis, also known as scleroderma, causes the hardening of the skin and connective tissues. In many cases, the disease can also damage vital organs, including the heart, kidneys, lungs, and... Read moreHematology
view channel
New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
Clonal cytopenia of undetermined significance (CCUS) is a blood disorder commonly found in older adults, characterized by mutations in blood cells and a low blood count, but without any obvious cause or... Read more
Non-Invasive Prenatal Test for Fetal RhD Status Demonstrates 100% Accuracy
In the United States, approximately 15% of pregnant individuals are RhD-negative. However, in about 40% of these cases, the fetus is also RhD-negative, making the administration of RhoGAM unnecessary.... Read moreImmunology
view channel
Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer
Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more
Machine Learning-Enabled Blood Test Predicts Immunotherapy Response in Lymphoma Patients
Chimeric antigen receptor (CAR) T-cell therapy has emerged as one of the most promising recent developments in the treatment of blood cancers. However, over half of non-Hodgkin lymphoma (NHL) patients... Read moreMicrobiology
view channel
Handheld Device Delivers Low-Cost TB Results in Less Than One Hour
Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more
New AI-Based Method Improves Diagnosis of Drug-Resistant Infections
Drug-resistant infections, particularly those caused by deadly bacteria like tuberculosis and staphylococcus, are rapidly emerging as a global health emergency. These infections are more difficult to treat,... Read more
Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours
Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read morePathology
view channel
New Error-Corrected Method to Help Detect Cancer from Blood Samples Alone
"Liquid biopsy" technology, which relies on blood tests for early cancer detection and monitoring cancer burden in patients, has the potential to transform cancer care. However, detecting the mutational... Read more
"Metal Detector" Algorithm Hunts Down Vulnerable Tumors
Scientists have developed an algorithm capable of functioning as a "metal detector" to identify vulnerable tumors, marking a significant advancement in personalized cancer treatment. This breakthrough... Read more
Novel Technique Uses ‘Sugar’ Signatures to Identify and Classify Pancreatic Cancer Cell Subtypes
Pancreatic cancer is often asymptomatic in its early stages, making it difficult to detect until it has progressed. Consequently, only 15% of pancreatic cancers are diagnosed early enough to allow for... Read moreTechnology
view channel
Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples
Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more
Innovative, Label-Free Ratiometric Fluorosensor Enables More Sensitive Viral RNA Detection
Viruses present a major global health risk, as demonstrated by recent pandemics, making early detection and identification essential for preventing new outbreaks. While traditional detection methods are... Read moreIndustry
view channel
Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions
Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Grifols and Tecan’s IBL Collaborate on Advanced Biomarker Panels
Grifols (Barcelona, Spain), one of the world’s leading producers of plasma-derived medicines and innovative diagnostic solutions, is expanding its offer in clinical diagnostics through a strategic partnership... Read more